Subgroup analyses showed a significantly decreased hazard for breast cancer death for patients treated with pertuzumab in the HER2-type subgroup (aHR 0.46, 95% CI 0.4–0.86, p = 0.016, n = 619; Fig. 4c). Here, ERBB2 is linked to breast carcinoma.